There may be a second wave of COVID-19 vaccines coming. With the hopes of widespread approval of each company's SARS-CoV-2 vaccine, Novavax (NASDAQ: NVAX) is already up nearly 90% year to date while Ocugen (NASDAQ: OCGN) is up over 300% in the same time frame. Each pharma's future is determined by decisions soon to be made by regulatory bodies and both stocks being down over 40% from 52-week highs. But which is the better buy now?
Patrick Bafuma: To begin, let's take a look at Novavax. First, it touted a hopeful vaccine for pandemic avian flu along with various other ailments like swine flu and RSV. Historically, Novavax has splashed onto the scene of almost every communicable disease crisis only to wither away and occasionally reverse split. However, Ocugen is looking to get its first product on the market with serious promise.
Image source: Getty Images.
Source Fool.com